2026 Q3
Category: Press release
First Patient Dosed in Phase 1 Trial Evaluating Transgene’s and BioInvent’s BT-001 in Patients with Rectal Cancer
BT-001 rectacl cancer
Transgene to Present Preclinical Data on Novel Oncolytic Virus at SITC 2026 Supporting its Potential for Systemic Delivery
SITC 2026 Abstract
Transgene Will Present a Poster on Preclinical Data from a Novel Oncolytic Virus at SITC 2026
SITC 2026
Transgene To Participate in Investor Access
Investor Access
Transgene Extends its myvac® Platform, Further Establishing its Position as a Key Player in the Rapidly Emerging Individualized Cancer Immunotherapy Field
2026 Half Year results
Transgene and ProBioGen Expand Strategic Partnership with Additional License Agreement for AGE1.CR.pIX Cell Line
ProBioGen
Transgene and NEC Report 100% Three-Year Disease-Free Survival with TG4050 and Publish Phase 1 Results in Nature Communications
NatCom
Transgene to Present Preclinical Data Demonstrating Robust Protection Against Mpox with its Novel Scalable Cell Line-Derived MVA Vaccine Candidate (TG MVA(TM)) at WCID 2026
Mpox WCID
Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine
TG4070